Rate of incidental central nervous system meningioma detected in patients undergoing ¹⁸F-fluciclovine PET/CT imaging for evaluation of prostate cancer

Objective To evaluate the rate of incidental detection of central nervous system (CNS) meningioma in patients undergoing ¹⁸F-fluciclovine PET/computed tomography (CT) imaging for the evaluation of prostate cancer. Methods The reports of 850 ¹⁸F-fluciclovine PET/CT scans in 566 patients with pathologically proven prostate cancer performed from April 2017 to July 2019, were retrospectively reviewed for the presence of CNS meningioma. Results A total of 14 patients (2.8%) (age range: 54-82 years old) had abnormal focal intracranial ¹⁸F-fluciclovine uptake, all extra-axial in location (SUVmax range: 3.2-19.3). Two cases out of 14 (0.35%) were diagnosed as metastatic lesions. Twelve out of the 14 patients, had ¹⁸F-fluciclovine PET/CT imaging findings suspicious for CNS meningioma, 2 of them received another diagnosis on further imaging, and only 10 cases (2%) had the diagnosis of meningioma according to follow-up MRI and ¹⁸F-fluciclovine PET/CT. Conclusion Focal ¹⁸F-fluciclovine avid intracranial lesions incidentally detected in patients undergoing PET/CT imaging for prostate cancer are most often CNS meningiomas.